ArticleInternational journal of women's health2025
Effects of Different Gonadotropin-Releasing Hormone Agonists on IVF/ICSI-ET Outcomes in Long Protocol: A Retrospective Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of Goserelin in Gynecological Disorders.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triptorelin acetate, leuprorelin and goserelin acetate were three commonly used gonadotropin-releasing hormone agonist (GnRH-a) formulations in IVF/ICSI-ET. However, current knowledge about the real-world effects on clinical outcomes of different GnRH-a formulations is limited. In this study, we aimed to compare the clinical outcomes of IVF/ICSI-ET using different GnRH-a formulations in long protocol during follicle phase. Methods: This is a retrospective study. A total of 154 infertile women undergoing IVF/ICSI-ET in long protocol during follicle phase from September 2019 to December 2023 were assigned to three groups according to different GnRH-a formulations (A: triptorelin acetate; B: leuprorelin; C: goserelin acetate). The baseline information, ovulation induction outcomes and pregnancy outcomes were compared among three groups. Student's Results: Groups A, B and C included 94, 36 and 24 patients, respectively. Compared with groups A and B, group C had significantly smaller total amount of gonadotropin (A vs B vs C: 2224.20±700.02 U vs 2266.67±884.01 U vs 1685.94±360.24 U) and shouter days of using gonadotropin (A vs B vs C: 11.61±1.91 days vs 11.83±2.48 days vs 9.50±0.98 days) ( Conclusion: Goserelin acetate was found to have good pregnancy outcomes in IVF/ICSI-ET with small amount and shout using days of gonadotropin, but there is a lack of statistical significance when compared to the pregnancy outcomes of triptorelin acetate and leuprorelin. The findings need future confirmation in larger trials or meta-analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.